Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
P/S ratio for Organovo Holdings, Inc. (ONVO)
P/S ratio as of 2023: 86.42
According to Organovo Holdings, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 86.42. At the end of 2022 the company had a P/S ratio of 51.57.
P/S ratio history for Organovo Holdings, Inc. from 2010 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 86.42 |
| 2022 | 51.57 |
| 2021 | 21.82 |
| 2020 | 0.00 |
| 2019 | 24.19 |
| 2018 | 36.21 |
| 2017 | 24.00 |
| 2016 | 73.50 |
| 2015 | 131.78 |
| 2014 | 493.80 |
| 2013 | 1474.37 |
| 2012 | 93.73 |
| 2010 | 0.00 |